pharmafileJuly 31, 2018
Tag: EU , Biological analogues
The Novartis subsidiary Sandoz, gained approval for its anti-inflammatory biosimilar Hyrimoz, which will be available as a 40mg pre filled syringe for treatment of a range of conditions. The drug however, will not be available in the UK before 16 October 2018.
The approval marks Sandoz ’sixth approved biosimilar medicine in Europe and the company’s fourth biosimilar approval in the past 18 months. The recent approval reaffirms Sandoz’ move towards leadership in regards to biosimilar development.
The reference drug which is sold under the brand name Humira was the first monoclonal antibody approved by the FDA and the third TNF inhibitor approved in the United States. While the immunosuppressive medication, which was originally marketed and manufactured by Abbot Laboratories, currently costs $4370 each month in the United States, the NHS spends £500 million a year on Humira. However the branded drug’s patent expired in 2016.
As such the biosimilar may allow for significant savings in both Europe and the United Kingdom. The availability of biosimilars in general could save the NHS up to £300 million each year.
-----------------------------------------------------------------------------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of en-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: